Vanguard Small-Cap Growth (VBK) Shares Cross Above 200 DMA
52 Week Range of VBK: VBK's stock has a 52-week low of $214.77 and a high of $304.59, with the last trade recorded at $269.36.
Author's Opinion Disclaimer: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Analyst Views on VBK
About the author
IBRX Stock Gains Retail Enthusiasm Following Saudi FDA Approval of Company's Bladder Cancer Immunotherapy
Expansion Plans: Immunity Bio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa, partnering with local pharmaceutical firm Bio Pharma Cigalah.
Clinical Study Update: Enrollment for the QUILT-2005 study evaluating ANKTIVA in early-stage bladder cancer is expected to be completed by Q2 2026, with potential biological license application by the end of the year.
Stock Performance: Immunity Bio's stock surged 8% following the approval of ANKTIVA by the Saudi Food and Drug Authority, marking a significant regulatory milestone alongside existing authorizations in the US, UK, and EU.
Market Sentiment: Retail sentiment around Immunity Bio remains extremely bullish, with speculation that the approval could double the company's product revenue, reflecting a positive outlook among investors.
Analysts Predict 21% Growth Potential for VBK
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $361.04, indicating a potential upside of 20.84% from its current trading price of $298.77.
Notable Holdings with Upside Potential: Key underlying holdings of VBK, such as Driven Brands Holdings Inc (DRVN), Phreesia Inc (PHR), and Zeta Global Holdings Corp (ZETA), show significant upside potential, with target prices suggesting increases of 56.06%, 53.11%, and 50.50% respectively.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.
Analysis Indicates VBK Could Reach $342
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $341.80, indicating a potential upside of 12.07% from its current trading price of $304.99.
Notable Holdings with Upside Potential: Key underlying holdings of VBK, such as Kiniksa Pharmaceuticals (KNSA), NET Power Inc (NPWR), and Kymera Therapeutics (KYMR), show significant upside potential based on analyst target prices, with KNSA having a target 24.84% higher than its current price.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent developments in the companies and their respective industries.
Analysts Predict 10% Growth Potential for VBK Holdings
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $336.53, indicating a potential upside of 10.46% from its recent trading price of $304.65.
Notable Holdings with Upside Potential: Key underlying holdings such as GoodRx Holdings (GDRX), Metsera Inc (MTSR), and HeartFlow Inc (HTFL) show significant upside potential, with target prices suggesting increases of 33.97%, 18.62%, and 13.90% respectively from their current prices.
Analysts Predict 12% Growth for VBK in the Future
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $335.05, indicating a potential upside of 12.25% from its current trading price of $298.49.
Notable Holdings with Upside Potential: Key underlying holdings such as Wolfspeed Inc (WOLF), Chime Financial Inc (CHYM), and Onestream Inc (OS) show significant upside potential, with target prices suggesting increases of 98.50%, 57.35%, and 54.72% respectively from their recent trading prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
ETF Outflow Warning: VBK, PTC, SOFI, TOST
VBK Share Price Analysis: VBK's share price is currently at $296.01, with a 52-week low of $214.77 and a high of $304.59, indicating a relatively stable position within its trading range.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function like stocks, allowing investors to buy and sell units that can be created or destroyed based on demand, impacting the underlying assets held within the ETFs.
IBRX Stock Gains Retail Enthusiasm Following Saudi FDA Approval of Company's Bladder Cancer Immunotherapy
Expansion Plans: Immunity Bio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa, partnering with local pharmaceutical firm Bio Pharma Cigalah.
Clinical Study Update: Enrollment for the QUILT-2005 study evaluating ANKTIVA in early-stage bladder cancer is expected to be completed by Q2 2026, with potential biological license application by the end of the year.
Stock Performance: Immunity Bio's stock surged 8% following the approval of ANKTIVA by the Saudi Food and Drug Authority, marking a significant regulatory milestone alongside existing authorizations in the US, UK, and EU.
Market Sentiment: Retail sentiment around Immunity Bio remains extremely bullish, with speculation that the approval could double the company's product revenue, reflecting a positive outlook among investors.
Analysts Predict 21% Growth Potential for VBK
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $361.04, indicating a potential upside of 20.84% from its current trading price of $298.77.
Notable Holdings with Upside Potential: Key underlying holdings of VBK, such as Driven Brands Holdings Inc (DRVN), Phreesia Inc (PHR), and Zeta Global Holdings Corp (ZETA), show significant upside potential, with target prices suggesting increases of 56.06%, 53.11%, and 50.50% respectively.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.
Analysis Indicates VBK Could Reach $342
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $341.80, indicating a potential upside of 12.07% from its current trading price of $304.99.
Notable Holdings with Upside Potential: Key underlying holdings of VBK, such as Kiniksa Pharmaceuticals (KNSA), NET Power Inc (NPWR), and Kymera Therapeutics (KYMR), show significant upside potential based on analyst target prices, with KNSA having a target 24.84% higher than its current price.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent developments in the companies and their respective industries.
Analysts Predict 10% Growth Potential for VBK Holdings
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $336.53, indicating a potential upside of 10.46% from its recent trading price of $304.65.
Notable Holdings with Upside Potential: Key underlying holdings such as GoodRx Holdings (GDRX), Metsera Inc (MTSR), and HeartFlow Inc (HTFL) show significant upside potential, with target prices suggesting increases of 33.97%, 18.62%, and 13.90% respectively from their current prices.
Analysts Predict 12% Growth for VBK in the Future
Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $335.05, indicating a potential upside of 12.25% from its current trading price of $298.49.
Notable Holdings with Upside Potential: Key underlying holdings such as Wolfspeed Inc (WOLF), Chime Financial Inc (CHYM), and Onestream Inc (OS) show significant upside potential, with target prices suggesting increases of 98.50%, 57.35%, and 54.72% respectively from their recent trading prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
ETF Outflow Warning: VBK, PTC, SOFI, TOST
VBK Share Price Analysis: VBK's share price is currently at $296.01, with a 52-week low of $214.77 and a high of $304.59, indicating a relatively stable position within its trading range.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function like stocks, allowing investors to buy and sell units that can be created or destroyed based on demand, impacting the underlying assets held within the ETFs.
